Beykin Gala, Goldberg Jeffrey L
Byers Eye Institute at Stanford University, 2452 Watson Ct, Palo Alto, CA 94303.
Curr Ophthalmol Rep. 2019;7(3):171-176. doi: 10.1007/s40135-019-00213-0. Epub 2019 Jul 23.
This article summarizes the current studies on molecular biomarkers with potential implications in diagnosis, prognosis, and response to treatment in patients with glaucoma.
Important advances have occurred in the understanding of the pathogenesis of glaucomatous neurodegeneration. Protein biomarkers associated with inflammatory, neurodegenerative, and other molecular pathways have been described in glaucoma patients in tear film, aqueous fluid, vitreous fluid, and serum, however, we are still far from having a clear picture of the whole molecular network that relates to the disease and its implications in clinical use.
Although more studies are needed, current and emerging molecular biomarkers candidates in glaucoma may eventually transition into clinical use and contribute to outline the concept of precision medicine and precision health in glaucoma.
本文总结了目前关于分子生物标志物的研究，这些生物标志物对青光眼患者的诊断、预后及治疗反应可能具有潜在影响。
在青光眼性神经变性发病机制的理解方面取得了重要进展。在泪膜、房水、玻璃体和血清中的青光眼患者中，已描述了与炎症、神经退行性变及其他分子途径相关的蛋白质生物标志物，然而，我们距离清晰了解与该疾病相关的整个分子网络及其在临床应用中的意义仍有很大差距。
尽管还需要更多研究，但目前及新出现的青光眼分子生物标志物候选物最终可能会转化为临床应用，并有助于勾勒青光眼精准医学和精准健康的概念。
